Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
Want to see HK:2135 full AI Analyst Report?
2135 Stock Chart & Stats
HK$0.17
<HK$0.01(0.99%)
At close: 4:00 PM EST
HK$0.17
<HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.11 - HK$0.20
Previous CloseN/A
Volume240.00K
Average Volume (3M)289.64K
Market Cap
HK$65.74M
Enterprise ValueHK$60.55M
Total Cash (Recent Filing)HK$57.82M
Total Debt (Recent Filing)HK$59.18M
Price to Earnings (P/E)33.0
Beta0.80
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation ImprovementA material reversal to strong operating cash flow and positive free cash flow in 2025 provides durable capacity to fund operations, service debt and invest in facilities or service expansion. Sustained cash generation reduces reliance on external financing and improves resilience versus prior deficit years.
Margin RecoverySharp margin improvement indicates better cost control and/or a more profitable service mix, creating a stronger earnings engine even with lower revenue. If structural, higher gross and EBITDA margins enhance durability of profits and provide a buffer against demand weakness and input-cost variability.
Manageable LeverageModerate leverage with a sizable equity base suggests balance-sheet flexibility and a limited absolute debt burden. Combined with improved cash flow, this enables options for gradual deleveraging, targeted reinvestment or absorbing shocks without immediate solvency pressure, supporting medium-term stability.
Bears Say
Thin Net MarginA reported net margin near 1% leaves minimal earnings cushion, making profitability highly sensitive to small revenue declines or cost increases. Historical multi-year losses underscore that the recent profit is fragile; sustainability requires consistent top-line or further structural margin improvements.
Cash-flow VolatilityDespite 2025 improvement, prior episodes of negative operating cash flow demonstrate volatile cash conversion over the cycle. This inconsistency raises risk that capital plans or debt servicing may need external funding in weaker periods, constraining long-term strategic investments.
Low Return On EquityROE near 1.7% indicates limited shareholder value creation following several years of negative returns. Even with recent operational gains, persistently low ROE suggests inefficiencies or underutilized capital, meaning the company may struggle to deliver attractive long-term returns without structural revenue or margin expansion.
Raily Aesthetic Medicine International Holdings Limited News
2135 FAQ
What was Raily Aesthetic Medicine International Holdings Limited’s price range in the past 12 months?
Raily Aesthetic Medicine International Holdings Limited lowest stock price was HK$0.10 and its highest was HK$0.20 in the past 12 months.
What is Raily Aesthetic Medicine International Holdings Limited’s market cap?
Raily Aesthetic Medicine International Holdings Limited’s market cap is HK$65.74M.
When is Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date?
Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date is Aug 21, 2026 which is in 66 days.
How were Raily Aesthetic Medicine International Holdings Limited’s earnings last quarter?
Raily Aesthetic Medicine International Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.019 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.019.
Is Raily Aesthetic Medicine International Holdings Limited overvalued?
According to Wall Street analysts Raily Aesthetic Medicine International Holdings Limited’s price is currently Overvalued.
Does Raily Aesthetic Medicine International Holdings Limited pay dividends?
Raily Aesthetic Medicine International Holdings Limited does not currently pay dividends.
What is Raily Aesthetic Medicine International Holdings Limited’s EPS estimate?
Raily Aesthetic Medicine International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raily Aesthetic Medicine International Holdings Limited have?
Raily Aesthetic Medicine International Holdings Limited has 557,077,330 shares outstanding.
What happened to Raily Aesthetic Medicine International Holdings Limited’s price movement after its last earnings report?
Raily Aesthetic Medicine International Holdings Limited reported an EPS of HK$0.019 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Raily Aesthetic Medicine International Holdings Limited?
Currently, no hedge funds are holding shares in HK:2135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Raily Aesthetic Medicine International Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.26%
12-Months-Change
Fundamentals
Return on Equity
1.67%
Trailing 12-Months
Asset Growth
-0.48%
Trailing 12-Months
Company Description
Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
Raily Aesthetic Medicine International Holdings Limited (2135) Earnings & Revenues
Technical Analysis
Beauty Farm Medical & Health Industry, Inc.
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
Medicskin Holdings Ltd.
―
Saint Bella Inc.
―